Third Arc Bio Investors 2026

Third Arc Bio — investors and similar companies (62)

Third Arc Bio's investor syndicate for 2026, drawn from verified round records: 14 distinct firms and angels appear on the cap table, including Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs Alternatives, BVF Partners LP. Third Arc Bio is tracked in Biotech and headquartered in Boston, USA.

The companies listed below are ranked by how much of that syndicate they share, so the overlap you see is backer-based rather than sector-based. Every investor name links to that firm's own profile with its full tracked portfolio, and every company links to its funding record.

• Verified backers on record: 14
• Total disclosed funding: $165M
• Latest tracked round: Series A (2024-07-23)
• Sector: Biotech
• Headquarters: Boston, USA

• Vida Ventures
• Cormorant Asset Management
• Hillhouse Investment
• Omega Funds
• Goldman Sachs Alternatives
• BVF Partners LP
• T. Rowe Price Associates, Inc.
• Janus Henderson Investors
• abrdn Inc.
• Marshall Wace
• Foresite Capital
• Logos Capital
• Freepoint Capital Group
• AbbVie Ventures
• Parabilis Medicines — shares Janus Henderson Investors
• Kashable — shares Goldman Sachs Alternatives
• Delfi Diagnostics — shares Foresite Capital
• Decibel Therapeutics — shares Foresite Capital
• Hexagon Bio — shares Vida Ventures
• Crossover Health — shares Foresite Capital
• Nuvation Bio — shares Omega Funds
• ProfoundBio — shares Janus Henderson Investors
• Ray Therapeutics — shares Janus Henderson Investors +1
• Verve Therapeutics — shares Cormorant Asset Management +2
• ITeos Therapeutics — shares Janus Henderson Investors
• BridgeBio Oncology Therapeutics — shares Cormorant Asset Management +1
• Obsidian Therapeutics — shares Foresite Capital +1
• Amunix — shares Omega Funds +1
• MiniMax — shares Hillhouse Investment
• Ripple — shares Marshall Wace
• BioNTech.de — shares Janus Henderson Investors
• Neumora Therapeutics — shares Logos Capital
• Synthego — shares Logos Capital
• Immunic Therapeutics — shares Omega Funds
• Quell Therapeutics — shares Janus Henderson Investors
• Ollin Biosciences — shares Foresite Capital
• Metagenomi — shares Marshall Wace
• Pardes Biosciences — shares Foresite Capital
• MoEngage — shares Goldman Sachs Alternatives
• Enliven Therapeutics — shares Cormorant Asset Management +2
• EpimAb Biotherapeutics — shares Cormorant Asset Management
• Aviceda Therapeutics — shares Omega Funds
• Minerva Neuroscience — shares Janus Henderson Investors +2
• Upstream Bio — shares Omega Funds
• Black Diamond Therapeutics — shares Janus Henderson Investors +1
• QScale — shares Goldman Sachs Alternatives
• Celonis
• Cue — shares Foresite Capital
• Gracell Biotechnologies — shares Janus Henderson Investors +1
• Mammoth Biosciences — shares Foresite Capital
• Angitia Biopharmaceuticals — shares Janus Henderson Investors
• Affinivax — shares Foresite Capital
• Wallbox — shares Janus Henderson Investors
• Kardigan
• Triveni Bio — shares Janus Henderson Investors +2
• Diagonal Therapeutics — shares Janus Henderson Investors
• Alterome Therapeutics — shares Goldman Sachs Alternatives +1
• OnKure Therapeutics — shares Cormorant Asset Management
• Remix Therapeutics — shares Foresite Capital
• ADARx Pharmaceuticals — shares Cormorant Asset Management +1
• PACT Pharma — shares Vida Ventures
• Kinnate Biopharma — shares Foresite Capital +3

Third Arc Bio funding profile · All research reports